title: Neurocan is upregulated in injured brain and in cytokine-treated astrocytes.
abstract: Injury to the CNS results in the formation of the glial scar, a primarily astrocytic structure that represents an obstacle to regrowing axons. Chondroitin sulfate proteoglycans (CSPG) are greatly upregulated in the glial scar, and a large body of evidence suggests that these molecules are inhibitory to axon regeneration. We show that the CSPG neurocan, which is expressed in the CNS, exerts a repulsive effect on growing cerebellar axons. Expression of neurocan was examined in the normal and damaged CNS. Frozen sections labeled with anti-neurocan monoclonal antibodies 7 d after a unilateral knife lesion to the cerebral cortex revealed an upregulation of neurocan around the lesion. Western blot analysis of extracts prepared from injured and uninjured tissue also revealed substantially more neurocan in the injured CNS. Western blot analysis revealed neurocan and the processed forms neurocan-C and neurocan-130 to be present in the conditioned medium of highly purified rat astrocytes. The amount detected was increased by transforming growth factor beta and to a greater extent by epidermal growth factor and was decreased by platelet-derived growth factor and, to a lesser extent, by interferon gamma. O-2A lineage cells were also capable of synthesizing and processing neurocan. Immunocytochemistry revealed neurocan to be deposited on the substrate around and under astrocytes but not on the cells. Astrocytes therefore lack the means to retain neurocan at the cell surface. These findings raise the possibility that neurocan interferes with axonal regeneration after CNS injury.
authors.affiliation: Physiological Laboratory, University of Cambridge, Cambridge CB2 3EG, United Kingdom.
authors.forename: R A
authors.initials: RA
authors.lastname: Asher
authors.forename: D A
authors.initials: DA
authors.lastname: Morgenstern
authors.forename: P S
authors.initials: PS
authors.lastname: Fidler
authors.forename: K H
authors.initials: KH
authors.lastname: Adcock
authors.forename: A
authors.initials: A
authors.lastname: Oohira
authors.forename: J E
authors.initials: JE
authors.lastname: Braistead
authors.forename: J M
authors.initials: JM
authors.lastname: Levine
authors.forename: R U
authors.initials: RU
authors.lastname: Margolis
authors.forename: J H
authors.initials: JH
authors.lastname: Rogers
authors.forename: J W
authors.initials: JW
authors.lastname: Fawcett
mesh_terms: D000818:Animals; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism; D015153:Blotting, Western; D001930:Brain Injuries / Q000378:metabolism*; D002478:Cells, Cultured; D011508:Chondroitin Sulfate Proteoglycans / Q000096:biosynthesis*; D017077:Culture Media, Conditioned; D016207:Cytokines / Q000494:pharmacology*; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D037181:Lectins, C-Type; D009419:Nerve Tissue Proteins / Q000096:biosynthesis*; D016501:Neurites / Q000378:metabolism; D058580:Neurocan; D051381:Rats; D017207:Rats, Sprague-Dawley; D015854:Up-Regulation
chemical_list: D011508:Chondroitin Sulfate Proteoglycans; D017077:Culture Media, Conditioned; D016207:Cytokines; D037181:Lectins, C-Type; D009419:Nerve Tissue Proteins; D058580:Neurocan; C076817:NCAN protein, human